Arrowhead Pharmaceuticals Inc

Company Profile

Arrowhead Pharmaceuticals Inc had its IPO on 1993-06-16 under the ticker symbol ARWR.

The company operates in the Healthcare sector and Biotechnology industry. Arrowhead Pharmaceuticals Inc has a staff strength of 397 employees.

Stock update

Shares of Arrowhead Pharmaceuticals Inc opened at $29.13 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $28.56 - $29.4, and closed at $29.1.

This is a -0.48% slip from the previous day's closing price.

A total volume of 739,839 shares were traded at the close of the day’s session.

In the last one week, shares of Arrowhead Pharmaceuticals Inc have increased by +4.08%.

Arrowhead Pharmaceuticals Inc's Key Ratios

Arrowhead Pharmaceuticals Inc has a market cap of $3.74 billion, indicating a price to book ratio of 8.0438 and a price to sales ratio of 14.7115.

In the last 12-months Arrowhead Pharmaceuticals Inc’s revenue was $272.80 million with a gross profit of $243.23 million and an EBITDA of $-140096000. The EBITDA ratio measures Arrowhead Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Arrowhead Pharmaceuticals Inc’s operating margin was -55.25% while its return on assets stood at -11.81% with a return of equity of -33.17%.

In Q1, Arrowhead Pharmaceuticals Inc’s quarterly earnings growth was a positive 9.8% while revenue growth was a negative 3.6%.

Arrowhead Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

111.1111

Trailing PE

0

PEG

-1.32

Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 111.1111 and a PEG multiple of -1.32. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arrowhead Pharmaceuticals Inc’s profitability.

Arrowhead Pharmaceuticals Inc stock is trading at a EV to sales ratio of 11.9672 and a EV to EBITDA ratio of -17.3173. Its price to sales ratio in the trailing 12-months stood at 14.7115.

Arrowhead Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$891.31 million

Total Liabilities

$87.15 million

Operating Cash Flow

$-36065000.00

Capital Expenditure

$27.31 million

Dividend Payout Ratio

0%

Arrowhead Pharmaceuticals Inc ended 2024 with $891.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $891.31 million while shareholder equity stood at $446.77 million.

Arrowhead Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $87.15 million in other current liabilities, 199000.00 in common stock, $-813405000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $134.96 million and cash and short-term investments were $481.01 million. The company’s total short-term debt was $2,711,000 while long-term debt stood at $0.

Arrowhead Pharmaceuticals Inc’s total current assets stands at $574.81 million while long-term investments were $78.83 million and short-term investments were $346.05 million. Its net receivables were $69.43 million compared to accounts payable of $9.56 million and inventory worth $0.

In 2024, Arrowhead Pharmaceuticals Inc's operating cash flow was $-36065000.00 while its capital expenditure stood at $27.31 million.

Comparatively, Arrowhead Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$29.1

52-Week High

$48.48

52-Week Low

$23.09

Analyst Target Price

$61.93

Arrowhead Pharmaceuticals Inc stock is currently trading at $29.1 per share. It touched a 52-week high of $48.48 and a 52-week low of $48.48. Analysts tracking the stock have a 12-month average target price of $61.93.

Its 50-day moving average was $31.42 and 200-day moving average was $32.64 The short ratio stood at 4.5 indicating a short percent outstanding of 0%.

Around 492.1% of the company’s stock are held by insiders while 6870.1% are held by institutions.